CLIENT CODE.





PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

REPORTING DATE

: 17/Sep/2024 03:50PM

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY REG. NO./LAB NO. : 122409170020

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Test Name Value Unit **Biological Reference interval**

SWASTHYA WELLNESS PANEL: 1.0 COMPLETE BLOOD COUNT (CBC)

RED BLOOD CELLS (RBCS) COUNT AND INDICES

HAEMOGLOBIN (HB)	14.9	gm/dL	12.0 - 17.0
by CALORIMETRIC			
RED BLOOD CELL (RBC) COUNT	4.56	Millions/cmm	3.50 - 5.00
by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE			
PACKED CELL VOLUME (PCV)	42.8	%	40.0 - 54.0
by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER			
MEAN CORPUSCULAR VOLUME (MCV)	93.9	fL	80.0 - 100.0
by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER			
MEAN CORPUSCULAR HAEMOGLOBIN (MCH)	32.8	pg	27.0 - 34.0
by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER			
MEAN CORPUSCULAR HEMOGLOBIN CONC. (MCHC)	34.9	g/dL	32.0 - 36.0
by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER			
RED CELL DISTRIBUTION WIDTH (RDW-CV)	12.2	%	11.00 - 16.00
by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER			
RED CELL DISTRIBUTION WIDTH (RDW-SD)	44.1	fL	35.0 - 56.0
by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER			
MENTZERS INDEX	20.59	RATIO	BETA THALASSEMIA TRAIT: < 13.0
by CALCULATED			IRON DEFICIENCY ANEMIA: >13.0
GREEN & KING INDEX	25.22	RATIO	BETA THALASSEMIA TRAIT:<= 65.0
by CALCULATED			IRON DEFICIENCY ANEMIA: > 65.0
WHITE BLOOD CELLS (WBCS)			
TOTAL LEUCOCYTE COUNT (TLC)	5720	/cmm	4000 - 11000
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			
NUCLEATED RED BLOOD CELLS (nRBCS)	NIL		0.00 - 20.00
by AUTOMATED 6 PART HEMATOLOGY ANALYZER			
NUCLEATED RED BLOOD CELLS (nRBCS) %	NIL	%	< 10 %
by CALCULATED BY AUTOMATED HEMATOLOGY ANALYZER			
DIFFERENTIAL LEUCOCYTE COUNT (DLC)			
NEUTROPHILS	55	%	50 - 70
by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY			



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY : 122409170020 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 03:50PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
LYMPHOCYTES by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	36	%	20 - 40
EOSINOPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	3	%	1 - 6
MONOCYTES by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	6	%	2 - 12
BASOPHILS by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	%	0 - 1
ABSOLUTE LEUKOCYTES (WBC) COUNT			
ABSOLUTE NEUTROPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	3146	/cmm	2000 - 7500
ABSOLUTE LYMPHOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	2059 ^L	/cmm	800 - 4900
ABSOLUTE EOSINOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	172	/cmm	40 - 440
ABSOLUTE MONOCYTE COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	343	/cmm	80 - 880
ABSOLUTE BASOPHIL COUNT by FLOW CYTOMETRY BY SF CUBE & MICROSCOPY	0	/cmm	0 - 110
PLATELETS AND OTHER PLATELET PREDICTIVE MARKE	ERS.		
PLATELET COUNT (PLT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	222000	/cmm	150000 - 450000
PLATELETCRIT (PCT) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	0.2	%	0.10 - 0.36
MEAN PLATELET VOLUME (MPV) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	9	fL	6.50 - 12.0
PLATELET LARGE CELL COUNT (P-LCC) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	50000	/cmm	30000 - 90000
PLATELET LARGE CELL RATIO (P-LCR) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE	22.3	%	11.0 - 45.0
PLATELET DISTRIBUTION WIDTH (PDW) by HYDRO DYNAMIC FOCUSING, ELECTRICAL IMPEDENCE NOTE: TEST CONDUCTED ON EDTA WHOLE BLOOD	16.3	%	15.0 - 17.0



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS, MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST





A PIONEER DIAGNOSTIC CENTRE

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY : 122409170020 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:23PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

GLYCOSYLATED HAEMOGLOBIN (HBA1C)

5.7 GLYCOSYLATED HAEMOGLOBIN (HbA1c): 4.0 - 6.4

WHOLF BLOOD

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

ESTIMATED AVERAGE PLASMA GLUCOSE 116.89 mg/dL 60.00 - 140.00

by HPLC (HIGH PERFORMANCE LIQUID CHROMATOGRAPHY)

INTERPRETATION:

AS PER AMERICAN DIABETES ASSOCIATION (ADA):				
REFERENCE GROUP	GLYCOSYLATED HEMOGL	OGIB (HBAIC) in %		
Non diabetic Adults >= 18 years	<5.7			
At Risk (Prediabetes)	5.7 – 6.4	1		
Diagnosing Diabetes	>= 6.5			
	Age > 19 Years			
	Goals of Therapy:	< 7.0		
Therapeutic goals for glycemic control	Actions Suggested:	>8.0		
	Age < 19 Years			
	Goal of therapy:	<7.5		

COMMENTS:

- 1.Glycosylated hemoglobin (HbA1c) test is three monthly monitoring done to assess compliace with therapeutic regimen in diabetic patients. 2. Since Hb1c reflects long term fluctuations in blood glucose concentration, a diabetic patient who has recently under good control may still have high concentration of HbAlc. Converse is true for a diabetic previously under good control but now poorly controlled.
- 3. Target goals of < 7.0 % may be beneficial in patients with short duration of diabetes, long life expectancy and no significant cardiovascular disease. In patients with significant complications of diabetes, limited life expectancy or extensive co-morbid conditions, targetting a goal of < 7.0% may not be
- 4.High HbA1c (>9.0 -9.5 %) is strongly associated with risk of development and rapid progression of microvascular and nerve complications 5. Any condition that shorten RBC life span like acute blood loss, hemolytic anemia falsely lower HbA1c results.
- 6.HbA1c results from patients with HbSS,HbSC and HbD must be interpreted with caution, given the pathological processes including anemia, increased red cell turnover, and transfusion requirement that adversely impact HbA1c as a marker of long-term gycemic control.
- 7. Specimens from patients with polycythemia or post-splenctomy may exhibit increse in HbA1c values due to a somewhat longer life span of the red cells



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)



A PIONEER DIAGNOSTIC CENTRE

: 17/Sep/2024 04:02PM

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY REG. NO./LAB NO. : 122409170020

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. **COLLECTION DATE** : 17/Sep/2024 01:52PM : 12504761

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Test Name Value Unit **Biological Reference interval**

ERYTHROCYTE SEDIMENTATION RATE (ESR)

ERYTHROCYTE SEDIMENTATION RATE (ESR)

0 - 20

REPORTING DATE

by RED CELL AGGREGATION BY CAPILLARY PHOTOMETRY

INTERPRETATION:

CLIENT CODE.

- 1. ESR is a non-specific test because an elevated result often indicates the presence of inflammation associated with infection, cancer and autoimmune disease, but does not tell the health practitioner exactly where the inflammation is in the body or what is causing it.
- 2. An ESR can be affected by other conditions besides inflammation. For this reason, the ESR is typically used in conjunction with other test such as C-reactive protein
- 3. This test may also be used to monitor disease activity and response to therapy in both of the above diseases as well as some others, such as systemic lupus erythematosus
 CONDITION WITH LOW ESR

A low ESR can be seen with conditions that inhibit the normal sedimentation of red blood cells, such as a high red blood cell count (polycythaemia), significantly high white blood cell count (leucocytosis), and some protein abnormalities. Some changes in red cell shape (such as sickle cells in sickle cell anaemia) also lower the ESR.

- ESR and C reactive protein (C-RP) are both markers of inflammation.
 Generally, ESR does not change as rapidly as does CRP, either at the start of inflammation or as it resolves.
 CRP is not affected by as many other factors as is ESR, making it a better marker of inflammation.
 If the ESR is elevated, it is typically a result of two types of proteins, globulins or fibrinogen.
- 5. Women tend to have a higher ESR, and menstruation and pregnancy can cause temporary elevations.
- 6. Drugs such as dextran, methyldopa, oral contraceptives, penicillamine procainamide, theophylline, and vitamin A can increase ESR, while aspirin, cortisone, and quinine may decrease it



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY : 122409170020 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:21PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval** Test Name

CLINICAL CHEMISTRY/BIOCHEMISTRY **GLUCOSE FASTING (F)**

GLUCOSE FASTING (F): PLASMA mg/dL NORMAL: < 100.0 110.86^H

by GLUCOSE OXIDASE - PEROXIDASE (GOD-POD) PREDIABETIC: 100.0 - 125.0 **DIABETIC:** > **0R** = **126.0**

IN ACCORDANCE WITH AMERICAN DIABETES ASSOCIATION GUIDELINES:

1. A fasting plasma glucose level below 100 mg/dl is considered normal.

2. A fasting plasma glucose level between 100 - 125 mg/dl is considered as glucose intolerant or prediabetic. A fasting and post-prandial blood test (after consumption of 75 gms of glucose) is recommended for all such patients.

3. A fasting plasma glucose level of above 125 mg/dl is highly suggestive of diabetic state. A repeat post-prandial is strongly recommended for all such patients. A fasting plasma glucose level in excess of 125 mg/dl on both occasions is confirmatory for diabetic state.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY REG. NO./LAB NO. : 122409170020

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:21PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
	LIPID PROFILE	: BASIC	
CHOLESTEROL TOTAL: SERUM by CHOLESTEROL OXIDASE PAP	244.12 ^H	mg/dL	OPTIMAL: < 200.0 BORDERLINE HIGH: 200.0 - 239.0 HIGH CHOLESTEROL: > OR = 240.0
TRIGLYCERIDES: SERUM by GLYCEROL PHOSPHATE OXIDASE (ENZYMATIC)	151.58 ^H	mg/dL	OPTIMAL: < 150.0 BORDERLINE HIGH: 150.0 - 199.0 HIGH: 200.0 - 499.0 VERY HIGH: > OR = 500.0
HDL CHOLESTEROL (DIRECT): SERUM by SELECTIVE INHIBITION	79.04	mg/dL	LOW HDL: < 30.0 BORDERLINE HIGH HDL: 30.0 - 60.0 HIGH HDL: > OR = 60.0
LDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	134.76 ^H	mg/dL	OPTIMAL: < 100.0 ABOVE OPTIMAL: 100.0 - 129.0 BORDERLINE HIGH: 130.0 - 159.0 HIGH: 160.0 - 189.0 VERY HIGH: > OR = 190.0
NON HDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	165.08 ^H	mg/dL	OPTIMAL: < 130.0 ABOVE OPTIMAL: 130.0 - 159.0 BORDERLINE HIGH: 160.0 - 189.0 HIGH: 190.0 - 219.0 VERY HIGH: > OR = 220.0
VLDL CHOLESTEROL: SERUM by CALCULATED, SPECTROPHOTOMETRY	30.32	mg/dL	0.00 - 45.00
TOTAL LIPIDS: SERUM by CALCULATED, SPECTROPHOTOMETRY	639.82	mg/dL	350.00 - 700.00
CHOLESTEROL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	3.09	RATIO	LOW RISK: 3.30 - 4.40 AVERAGE RISK: 4.50 - 7.0 MODERATE RISK: 7.10 - 11.0 HIGH RISK: > 11.0
LDL/HDL RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.7	RATIO	LOW RISK: 0.50 - 3.0 MODERATE RISK: 3.10 - 6.0 HIGH RISK: > 6.0



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

REPORTING DATE

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY REG. NO./LAB NO. : 122409170020

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. **COLLECTION DATE** : 17/Sep/2024 01:52PM : 12504761 : 17/Sep/2024 04:21PM

: P.K.R JAIN HEALTHCARE INSTITUTE **CLIENT ADDRESS** : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

TRIGLYCERIDES/HDL RATIO: SERUM 1.92^L **RATIO** 3.00 - 5.00

by CALCULATED, SPECTROPHOTOMETRY **INTERPRETATION:**

CLIENT CODE.

1. Measurements in the same patient can show physiological analytical variations. Three serial samples 1 week apart are recommended for Total Cholesterol, Triglycerides, HDL & LDL Cholesterol.

2. As per NLA-2014 guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.

3. Low HDL levels are associated with increased risk for Atherosclerotic Cardiovascular disease (ASCVD) due to insufficient HDL being available

to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.

4. NLA-2014 identifies Non HDL Cholesterol (an indicator of all atherogeniclipoproteins such as LDL, VLDL, IDL, Lpa, Chylomicron remnants) along with LDL-cholesterol as co-primary target for cholesterol lowering therapy. Note that major risk factors can modify treatment goals for LDL &Non

5. Additional testing for Apolipoprotein B, hsCRP,Lp(a) & LP-PLA2 should be considered among patients with moderate risk for ASCVD for risk refinement



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY REG. NO./LAB NO. : 122409170020

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:21PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

LIVER FUNCTION TEST (COMPLETE)

BILIRUBIN TOTAL: SERUM by DIAZOTIZATION, SPECTROPHOTOMETRY	0.99	mg/dL	INFANT: 0.20 - 8.00 ADULT: 0.00 - 1.20
BILIRUBIN DIRECT (CONJUGATED): SERUM by DIAZO MODIFIED, SPECTROPHOTOMETRY	0.25	mg/dL	0.00 - 0.40
BILIRUBIN INDIRECT (UNCONJUGATED): SERUM by CALCULATED, SPECTROPHOTOMETRY	0.74	mg/dL	0.10 - 1.00
SGOT/AST: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	16.77	U/L	7.00 - 45.00
SGPT/ALT: SERUM by IFCC, WITHOUT PYRIDOXAL PHOSPHATE	13.03	U/L	0.00 - 49.00
AST/ALT RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.29	RATIO	0.00 - 46.00
ALKALINE PHOSPHATASE: SERUM by PARA NITROPHENYL PHOSPHATASE BY AMINO METHYL PROPANOL	73.6	U/L	40.0 - 130.0
GAMMA GLUTAMYL TRANSFERASE (GGT): SERUM by SZASZ, SPECTROPHTOMETRY	27.31	U/L	0.00 - 55.0
TOTAL PROTEINS: SERUM by BIURET, SPECTROPHOTOMETRY	6.84	gm/dL	6.20 - 8.00
ALBUMIN: SERUM by BROMOCRESOL GREEN	4.24	gm/dL	3.50 - 5.50
GLOBULIN: SERUM by CALCULATED, SPECTROPHOTOMETRY	2.6	gm/dL	2.30 - 3.50
A : G RATIO: SERUM by CALCULATED, SPECTROPHOTOMETRY	1.63	RATIO	1.00 - 2.00

INTERPRETATION

NOTE:- To be correlated in individuals having SGOT and SGPT values higher than Normal Referance Range.

USE:- Differential diagnosis of diseases of hepatobiliary system and pancreas.

INCREASED:

DRUG HEPATOTOXICITY_	> 2
ALCOHOLIC HEPATITIS	> 2 (Highly Suggestive)
CIRRHOSIS	1.4 - 2.0
INTRAHEPATIC CHOLESTATIS	> 1.5



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY REG. NO./LAB NO. : 122409170020

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:21PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

HEPATOCELLULAR CARCINOMA & CHRONIC HEPATITIS > 1.3 (Slightly Increased)

1. Acute Hepatitis due to virus, drugs, toxins (with AST increased 3 to 10 times upper limit of normal)

2. Extra Hepatic cholestatis: 0.8 (normal or slightly decreased).

PROGNOSTIC SIGNIFICANCE:

	NORMAL	< 0.65
	GOOD PROGNOSTIC SIGN	0.3 - 0.6
П	POOR PROGNOSTIC SIGN	1.2 - 1.6



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)



CLIENT CODE.





PKR JAIN HEALTHCARE INSTITUTE NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

: 17/Sep/2024 04:21PM

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY : 122409170020 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

: P.K.R JAIN HEALTHCARE INSTITUTE

Test Name	Value	Unit	Biological Reference interval
-----------	-------	------	-------------------------------

KIDNEY FUNCTION TEST (COMPLETE)

REPORTING DATE

	KIDINE	A LONCTION 1521 (COI	VIPLETE)	
UREA: SERUM by UREASE - GLUTAMATE DEHYDROGEI	NASE (GLDH)	27.04	mg/dL	10.00 - 50.00
CREATININE: SERUM by ENZYMATIC, SPECTROPHOTOMETER	Y	1.04	mg/dL	0.40 - 1.40
BLOOD UREA NITROGEN (BUN): SER by CALCULATED, SPECTROPHOTOMETE		12.64	mg/dL	7.0 - 25.0
BLOOD UREA NITROGEN (BUN)/CRE. RATIO: SERUM by CALCULATED, SPECTROPHOTOMETR	ATININE	12.15	RATIO	10.0 - 20.0
UREA/CREATININE RATIO: SERUM by CALCULATED, SPECTROPHOTOMETR	RY	26	RATIO	
URIC ACID: SERUM by URICASE - OXIDASE PEROXIDASE		4.86	mg/dL	3.60 - 7.70
CALCIUM: SERUM by ARSENAZO III, SPECTROPHOTOMETR	Y	9.01	mg/dL	8.50 - 10.60
PHOSPHOROUS: SERUM by PHOSPHOMOLYBDATE, SPECTROPH ELECTROLYTES		3.71	mg/dL	2.30 - 4.70
SODIUM: SERUM by ISE (ION SELECTIVE ELECTRODE)		137.8	mmol/L	135.0 - 150.0
POTASSIUM: SERUM by ISE (ION SELECTIVE ELECTRODE)		4.9	mmol/L	3.50 - 5.00
CHLORIDE: SERUM by ISE (ION SELECTIVE ELECTRODE) ESTIMATED GLOMERULAR FILTERAT	ION RATE	103.35	mmol/L	90.0 - 110.0
ESTIMATED GLOMERULAR FILTERAT	ION RATE	89.1		

ESTIMATED GLOMERULAR FILTERATION RATE

(eGFR): SERUM by CALCULATED **INTERPRETATION:**

To differentiate between pre- and post renal azotemia.

INCREASED RATIO (>20:1) WITH NORMAL CREATININE:

- 1. Prerenal azotemia (BUN rises without increase in creatinine) e.g. heart failure, salt depletion, dehydration, blood loss) due to decreased glomerular filtration rate.
- 2. Catabolic states with increased tissue breakdown.



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY REG. NO./LAB NO. : 122409170020

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM

BARCODE NO. **COLLECTION DATE** : 17/Sep/2024 01:52PM : 12504761 CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:21PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

3. GI haemorrhage.

4. High protein intake.

5. Impaired renal function plus

6. Excess protein intake or production or tissue breakdown (e.g. infection, GI bleeding, thyrotoxicosis, Cushing's syndrome, high protein diet, burns, surgery, cachexia, high fever).

7. Urine reabsorption (e.g. ureter colostomy)

8. Reduced muscle mass (subnormal creatinine production)

9. Certain drugs (e.g. tetracycline, glucocorticoids)

INCREASED RATIO (>20:1) WITH ELEVATED CREATININE LEVELS:

- 1. Postrenal azotemia (BUN rises disproportionately more than creatinine) (e.g. obstructive uropathy).
- 2. Prerenal azotemia superimposed on renal disease.

DECREASED RATIO (<10:1) WITH DECREASED BUN:

- 1. Acute tubular necrosis.
- 2. Low protein diet and starvation.
- 3. Severe liver disease.
- 4. Other causes of decreased urea synthesis.
- 5. Repeated dialysis (urea rather than creatinine diffuses out of extracellular fluid).
- 6. Inherited hyperammonemias (urea is virtually absent in blood).
- 7. SIADH (syndrome of inappropiate antidiuretic harmone) due to tubular secretion of urea.
- 8. Pregnancy.

DECREASED RATIO (<10:1) WITH INCREASED CREATININE:

- 1. Phenacimide therapy (accelerates conversion of creatine to creatinine).
- 2. Rhabdomyolysis (releases muscle creatinine).
- 3. Muscular patients who develop renal failure.

INAPPROPIATE RATIO:

- 1. Diabetic ketoacidosis (acetoacetate causes false increase in creatinine with certain methodologies, resulting in normal ratio when dehydration should produce an increased BUN/creatinine ratio).
- 2. Cephalosporin therapy (interferes with creatinine measurement). ESTIMATED GLOMERULAR FILTERATION RATE:

STIMATED GEOWERGEART IETERATION RATE.					
CKD STAGE	DESCRIPTION	GFR (mL/min/1.73m2)	ASSOCIATED FINDINGS		
G1	Normal kidney function	>90	No proteinuria		
G2	Kidney damage with	>90	Presence of Protein,		
	normal or high GFR		Albumin or cast in urine		
G3a	Mild decrease in GFR	60 -89			
G3b	Moderate decrease in GFR	30-59			
G4	Severe decrease in GFR	15-29			
G5	Kidney failure	<15			



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)







A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY REG. NO./LAB NO. : 122409170020

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. **COLLECTION DATE** : 17/Sep/2024 01:52PM : 12504761

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:21PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name Value Unit **Biological Reference interval**

COMMENTS:

1. Estimated Glomerular filtration rate (eGFR) is the sum of filtration rates in all functioning nephrons and so an estimation of the GFR provides a measure of functioning nephrons of the kidney.

2. eGFR calculated using the 2009 CKD-EPI creatinine equation and GFR category reported as per KDIGO guideline 2012

3. In patients, with eGFR creatinine between 45-59 ml/min/1.73 m2 (G3) and without any marker of Kidney damage, It is recommended to measure eGFR with Cystatin C for confirmation of CKD

4. eGFR category G1 OR G2 does not fullfill the criteria for CKD, in the absence of evidence of Kidney Damage
5. In a suspected case of Acute Kidney Injury (AKI), measurement of eGFR should be done after 48-96 hours of any Intervention or procedure
6. eGFR calculated by Serum Creatinine may be less accurate due to certain factors like Race, Muscle Mass, Diet, Certain Drugs. In such cases, eGFR should be calculated using Serum Cystatin C
7. A decrease in eGFR implies either progressive renal disease, or a reversible process causing decreased nephron function (eg, severe dehydration).

ADVICE:

KDIGO guideline, 2012 recommends Chronic Kidney Disease (CKD) should be classified based on cause, eGFR category and Albuminuria (ACR) category. GFR & ACR category combined together reflect risk of progression and helps Clinician to identify the individual who are progressing at more rapid rate than anticipated



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY)





PKR JAIN HEALTHCARE INSTITUTE

NASIRPUR, Hissar Road, AMBALA CITY- (Haryana)

A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 **■** pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY : 122409170020 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. **COLLECTION DATE** : 17/Sep/2024 01:52PM : 12504761

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:21PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Value Unit **Biological Reference interval** Test Name

CLINICAL PATHOLOGY URINE ROUTINE & MICROSCOPIC EXAMINATION

PHYSICAL EXAMINATION

QUANTITY RECIEVED	30	ml
by DIP STICK/REELECTANCE SPECTROPHOT	TOMETRY	

PALE YELLOW PALE YELLOW **COLOUR**

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY TRANSPARANCY **CLEAR CLEAR**

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY 1.02 1.002 - 1.030 SPECIFIC GRAVITY

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY **CHEMICAL EXAMINATION**

REACTION **ACIDIC**

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

PROTEIN NEGATIVE (-ve) NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY **SUGAR NEGATIVE** (-ve) **NEGATIVE** (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY рΗ 5.0 - 7.5

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

BILIRUBIN NEGATIVE (-ve) **NEGATIVE** (-ve) by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

NITRITE NEGATIVE (-ve) **NEGATIVE** (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY. EU/dL **NOT DETECTED UROBILINOGEN** 0.2 - 1.0

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY KETONE BODIES NEGATIVE (-ve) NEGATIVE (-ve)

by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

NEGATIVE (-ve) NEGATIVE (-ve) **BLOOD** by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

NEGATIVE (-ve) ASCORBIC ACID **NEGATIVE** (-ve) by DIP STICK/REFLECTANCE SPECTROPHOTOMETRY

MICROSCOPIC EXAMINATION



CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY)



440 Dated 17.5.2012 u/s 80 G OF INCOME TAX ACT. PAN NO. AAAAP1600. REPORT ATTRACTS THE CONDITIONS PRINTED OVERLEAF (P.T.O.)





A PIONEER DIAGNOSTIC CENTRE

■ 0171-2532620, 8222896961 ■ pkrjainhealthcare@gmail.com

NAME : Mr. AMANPAL SINGH

AGE/ GENDER : 47 YRS/MALE **PATIENT ID** : 1258213

COLLECTED BY : 122409170020 REG. NO./LAB NO.

REFERRED BY **REGISTRATION DATE** : 17/Sep/2024 01:38 PM BARCODE NO. : 12504761 **COLLECTION DATE** : 17/Sep/2024 01:52PM

CLIENT CODE. : P.K.R JAIN HEALTHCARE INSTITUTE REPORTING DATE : 17/Sep/2024 04:21PM

CLIENT ADDRESS : NASIRPUR, HISSAR ROAD, AMBALA CITY - HARYANA

Test Name	Value	Unit	Biological Reference interval
RED BLOOD CELLS (RBCs) by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)	/HPF	0 - 3
PUS CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	4-5	/HPF	0 - 5
EPITHELIAL CELLS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	2-3	/HPF	ABSENT
CRYSTALS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
CASTS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
BACTERIA by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
OTHERS by MICROSCOPY ON CENTRIFUGED URINARY SEDIMENT	NEGATIVE (-ve)		NEGATIVE (-ve)
TRICHOMONAS VAGINALIS (PROTOZOA) by microscopy on centrifuged urinary sediment	ABSENT		ABSENT

*** End Of Report



DR.VINAY CHOPRA CONSULTANT PATHOLOGIST MBBS, MD (PATHOLOGY & MICROBIOLOGY) MBBS, MD (PATHOLOGY)

DR.YUGAM CHOPRA CONSULTANT PATHOLOGIST

